Humoral hypercalcemic factor antagonists
US5149779A · kind A · utility
20Cited by
4References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 26, 1990 |
| Grant date | Sep 22, 1992 |
| Priority date | — |
| Expiry date | Jul 26, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/635
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Peptide analogues of human humoral hypercalcemic factor (hHCF) that contain a lactam bridge act as inhibitors of the naturally occurring peptide. A lactam bridge between Lys and Asp situated five residues (inclusive) apart confers rigidity to that region of the peptide, and enhances the helical nature and metabolic stability of the peptide analogue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.